Qualigen Therapeutics Inc (QLGN NASDAQ) stock market data APIs
$2.8481
-0.19(-6.7%)
as of December 17, 2025
Try our APIs with
free plan!
Qualigen Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was founded in 1996 and is based in Carlsbad, California.
Prev. Close
2.8481
Open
2.6545
High
2.9533
Low
2.6078
52 wk Range
1.61-6.48
Market Cap
6 526 K
P/E Ratio
1.1263
Shares Outstanding
2 033 K
Revenue
4 984 K
EPS
-1.0019
Beta
0.282
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Qualigen Therapeutics Inc data using free add-ons & libraries
Get Qualigen Therapeutics Inc Fundamental Data
Qualigen Therapeutics Inc Fundamental data includes:
- Net Revenue: 4 984 K
- EBITDA: -6 886 340
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-18
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Qualigen Therapeutics Inc News
New
Qualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. (Nasdaq: AIXC) Following November 20 Nasdaq Ceremony and Announces Transition into AI × Web3 Strategy
Shareholders approved all proposals, confirming Faraday Future Intelligent Electric Inc. (“Faraday Future”) as the Company’s new majority and controlling shareholder. Faraday Future will nominat...
Faraday Future Reports Financial Results for Q3 2025
FX Super One has entered the pre-production phase at its Hanford manufacturing factory with the target of the first FX Super One pre-production vehicle rolling off the line in the U.S. in the near fut...
Qualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025
Dubai, UAE / Beijing, China, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics Inc. (NASDAQ: QLGN) (“Qualigen”, “QLGN” or the “Company”), a publicly-traded technology company major...
Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: The Whole FX Team is Now in Full Sprint Mode for the Year-End Off-Line Target for the Company’s First FX Super One Vehicle
The UAE launch of the FX Super One will take place on October 28 at the Armani Hotel, Burj Khalifa, Dubai. LOS ANGELES, Oct. 19, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (N...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
